Gilead Sciences, Inc. · NASDAQ:GILD
Gilead Sciences — Investor Day (December 2024)
82 slides from Gilead Sciences's investor day presentation, Dec 10, 2024
Slide 1: HIV Analyst & Investor Event
HIV Analyst & Investor Event 10 December 2024 10 December 2024 FOR INVESTOR USE ONLY, NOT FOR PROMOTIONAL USE.
Slide 2: Forward-Looking Statements
Forward-Looking Statements Statements included in this presentation that are not historical in nature are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Gilead cautions readers that forward-looking statements are subject to certain risks and un
Slide 3: Agenda
Agenda Morning Session Afternoon Session 10:30am – 12:00pm 1:30pm – 3:00pm Leading HIV Innovation: Our Legacy & Our Future Transformational HIV PrEP Program & Strategy Welcome and Introduction Global Strategy for PrEP Daniel O’Day・ Chairman & CEO Tanya Monga・ SVP Global Commercial Strategy & Operati
Slide 4: Introduction
Introduction Daniel O’Day Chairman & Chief Executive Officer
Slide 5: Extending Our HIV Leadership Into Late 2030s & Beyond
Extending Our HIV Leadership Into Late 2030s & Beyond SETTING A NEW STANDARD IN HIV TREATMENT TRANSFORMATIONAL HIV PREVENTION Next Wave of Gilead HIV Innovation Unparalleled PrEP Program Meaningfully Extends Our Leadership Offers New Possibilities • Annual ~2-3% treatment market growth • Lenacapavir
Slide 6: Our Leadership, Innovation & Vision in HIV
Our Leadership, Innovation & Vision in HIV To m a s C i h l a r, P h D SVP Research, Virology Discovery
Slide 7: Gilead's Long-Standing Leadership in HIV
Leading HIV Innovation Setting a New HIV Treatment Standard Transforming HIV PrEP Gilead’s Long-Standing Leadership in HIV First Single Tablet First Medication #1 Prescribed HIV First Twice-Yearly 1st Regimen for HIV Treatment for HIV Prevention Treatment Regimen Ever Long-acting HIV Drug Truvada Pr
Slide 8: Persistent Commitment to Innovation Leads to Lenacapavir
Leading HIV Innovation Setting a New HIV Treatment Standard Transforming HIV PrEP Persistent Commitment to Innovation Leads to Lenacapavir Least desirable Lenacapavir First-in-class HIV capsid inhibitor F F Potency (EC50, nM) F F H N Cl N N O H N N F3C N N O S O CF3 O S O Fast Track Breakthrough NDA
Slide 9: Lenacapavir is the Foundation of Our Long-Acting Portfolio
Leading HIV Innovation Setting a New HIV Treatment Standard Transforming HIV PrEP Lenacapavir is the Foundation of Our Long-Acting Portfolio HIV Virus entry Lenacapavir is a small molecule with… • No overlapping resistance • Exceptional potency with existing HIV medicines (EC50 = 100 pM) • Proven cl
Slide 10: Developing Game-Changing Options for Treatment & PrEP
Leading HIV Innovation Setting a New HIV Treatment Standard Transforming HIV PrEP Developing Game-Changing Options for Treatment & PrEP Treatment PrEP Injectable Oral Injectable Oral Innovation Continuum Game-Changers (Ultimate Goal) Twice-Yearly Monthly Once-Yearly Monthly or Weekly Quarterly Weekl
Slide 11: Pursuing a Broad Portfolio of Long-Acting Partner Molecules
Leading HIV Innovation Setting a New HIV Treatment Standard Transforming HIV PrEP Pursuing a Broad Portfolio of Long-Acting Partner Molecules 1 Broadly Neutralizing Abs 2 Nucleoside Reverse Transcriptase 4 Integrase Inhibitors 3 5 Capsid Inhibitors Translocation Inhibitors (LEN prodrugs) Teropavimab
Slide 12: Ultimate Innovation in Best-in-Class Partners for LEN
Leading HIV Innovation Setting a New HIV Treatment Standard Transforming HIV PrEP Ultimate Innovation in Best-in-Class Partners for LEN LEN Developing Long-Acting Injectable INSTIs to Combine with Lenacapavir for Twice-Yearly Dosing Continuous innovation to create new INSTIs >3,000 compounds Identif
Slide 13: Building Oral Dosing Flexibility Using Prodrug Chemistry
Leading HIV Innovation Setting a New HIV Treatment Standard Transforming HIV PrEP Building Oral Dosing Flexibility Using Prodrug Chemistry Once-Weekly Oral Once-Monthly Oral Utilizing Prodrugs to Optimize Oral Bioavailability GS-3107 GS-4182 LEN Prodrug LEN Prodrug Phase 1 ongoing Parent molecules s
Slide 14: Leveraging Deep Expertise to Advance Long-Acting Portfolio
Leading HIV Innovation Setting a New HIV Treatment Standard Transforming HIV PrEP Leveraging Deep Expertise to Advance Long-Acting Portfolio 13 HIV antivirals >125 countries approved in 23 years where Gilead Virology medicines are available 4,000+ Virology employees >16 million people across R&D, ma
Slide 15: Leading the HIV Treatment Market
Leading the HIV Treatment Market Ta n y a M o n g a SVP Global Commercial Strategy & Operations
Slide 16: Biktarvy Sets the Bar for HIV Treatment
Leading HIV Innovation Setting a New HIV Treatment Standard Transforming HIV PrEP Biktarvy Sets the Bar for HIV Treatment At 5 years follow-up: 98%+ #1 #1 >1M of participants achieved and maintained an prescribed therapy for prescribed therapy for people worldwide are undetectable viral load in M=E
Slide 17: Global Need to Increase Viral Suppression
Leading HIV Innovation Setting a New HIV Treatment Standard Transforming HIV PrEP Global Need to Increase Viral Suppression Globally, HIV & insufficient use of ARVs 1.3M ~25% remain an issue… New Annual HIV Infections1 of PWH not receiving treatment1 For Every 100 People with HIV:2 …including in the
Slide 18: Treatment Options Needed that Work for Everyone
Leading HIV Innovation Setting a New HIV Treatment Standard Transforming HIV PrEP Treatment Options Needed that Work for Everyone Stigma & Discrimination 40% of PWH fear taking their medication could reveal HIV status1 33% of PWH experience stress from daily regimens1 ~60% of PWH identified less fre
Slide 19: Gilead's Treatment Portfolio is the Broadest in Industry
Leading HIV Innovation Setting a New HIV Treatment Standard Transforming HIV PrEP Gilead’s Treatment Portfolio is the Broadest in Industry Company 1 Company 2 Once-Daily Oral Virally Suppressed, No other Complex Regimens1 Weekly Oral portfolio Monthly Oral addresses all these Quarterly Injectable ma
Slide 20: Innovation Maintains Treatment Leadership
Leading HIV Innovation Setting a New HIV Treatment Standard Transforming HIV PrEP Innovation Maintains Treatment Leadership Person-Centric U.S. Treatment Market Evolution Dosing Options Daily Oral Treated Market Growth LA Injectable Long-Acting 2024 Mid-2030s Orals & Weekly Oral Injectables 2-3% 2-3
Slide 21: Up to 7 Potential New Options for PWH by End of 2033
Leading HIV Innovation Setting a New HIV Treatment Standard Transforming HIV PrEP Up to 7 Potential New Options for PWH by End of 2033 GS-3107 + INSTI Monthly Oral Bictegravir Lenacapavir + Lenacapavir + GS-16141 Daily Oral Quarterly Injectable Lenacapavir Lenacapavir Lenacapavir GS-4182 + TAB + ZAB
Slide 22: Pioneering an Innovative Treatment Pipeline
Pioneering an Innovative Treatment Pipeline Jared Baeten, MD, PhD SVP Virology Therapeutic Area Head
Slide 23: Rapidly Advancing Innovative Treatment Pipeline
Leading HIV Innovation Setting a New HIV Treatment Standard Transforming HIV PrEP Rapidly Advancing Innovative Treatment Pipeline Pre-IND Phase 1 Phase 2 Phase 3 Daily Bictegravir + Lenacapavir Islatravir1 GS-1720 Weekly GS-4182 GS-58942 Monthly GS-16141 Quarterly Islatravir1,2 GS-62122 Lenacapavir
Slide 24: Rapidly Advancing Innovative Treatment Pipeline
Leading HIV Innovation Setting a New HIV Treatment Standard Transforming HIV PrEP Rapidly Advancing Innovative Treatment Pipeline Treatment- Virally Pre-IND Phase 1 Phase 2 Phase 3 Naive Suppressed Daily Bictegravir + Lenacapavir BIC/LEN — Islatravir1 LEN/ISL — GS-1720 Weekly GS-4182 + GS-1720 GS-41
Slide 25: Comprehensive Treatment Pipeline
Leading HIV Innovation Setting a New HIV Treatment Standard Transforming HIV PrEP Comprehensive Treatment Pipeline Evaluating Profile for Combination Selecting Ideal Partner Advancing Forward Daily Oral Bictegravir + Lenacapavir Lenacapavir + Islatravir (NRTTI) Weekly Oral GS-4182 (LEN prodrug) + GS
Slide 26: Comprehensive Treatment Pipeline
Leading HIV Innovation Setting a New HIV Treatment Standard Transforming HIV PrEP Comprehensive Treatment Pipeline Evaluating Profile for Combination Selecting Ideal Partner Advancing Forward Daily Oral Bictegravir + Lenacapavir Lenacapavir + Islatravir (NRTTI) Weekly Oral GS-4182 (LEN prodrug) + GS
Slide 27: BIC/LEN: Unique Option for Complex Regimens
Leading HIV Innovation Setting a New HIV Treatment Standard Transforming HIV PrEP BIC/LEN: Unique Option for Complex Regimens Once-Daily Oral Viral Suppression Maintained in PWH on Complex Regimens in Phase 2 (ARTISTRY-1) VS (HIV-1 RNA <50 c/mL) at Week 48 (FDA Snapshot) • Bictegravir (75mg) + lenac
Slide 28: Comprehensive Treatment Pipeline
Leading HIV Innovation Setting a New HIV Treatment Standard Transforming HIV PrEP Comprehensive Treatment Pipeline Evaluating Profile for Combination Selecting Ideal Partner Advancing Forward Daily Oral Bictegravir + Lenacapavir Lenacapavir + Islatravir (NRTTI) Weekly Oral GS-4182 (LEN prodrug) + GS
Slide 29: LEN/ISL: Positioned to be First Weekly Oral Regimen
Leading HIV Innovation Setting a New HIV Treatment Standard Transforming HIV PrEP LEN/ISL: Positioned to be First Weekly Oral Regimen Once-Weekly Oral Comparable Viral Suppression to Biktarvy at Week 48 94% 92% n= 49 48 52 52 Participants, % HIV-1 RNA <50 c/mL ISL + LEN (n=52) • Potency and half-lif
Slide 30: GS-4182/GS-1720: Weekly Oral for Naïve & Switch PWH
Leading HIV Innovation Setting a New HIV Treatment Standard Transforming HIV PrEP GS-4182/GS-1720: Weekly Oral for Naïve & Switch PWH Once-Weekly Oral GS-4182: Single Dose Maintains LEN GS-1720: Potent Oral INSTI w/Similar Concentrations Above Efficacy Target Antiviral Activity to BIC • First weekly
Slide 31: Comprehensive Treatment Pipeline
Leading HIV Innovation Setting a New HIV Treatment Standard Transforming HIV PrEP Comprehensive Treatment Pipeline Evaluating Profile for Combination Selecting Ideal Partner Advancing Forward Daily Oral Bictegravir + Lenacapavir Lenacapavir + Islatravir (NRTTI) Weekly Oral GS-4182 (LEN prodrug) + GS
Slide 32: GS-3107: LEN Prodrug w/Potential for Monthly Dosing
Leading HIV Innovation Setting a New HIV Treatment Standard Transforming HIV PrEP GS-3107: LEN Prodrug w/Potential for Monthly Dosing Once-Monthly Oral Single Oral Dose of GS-3107 & Lenacapavir Rat Model Rat Animal Dog Animal Model • GS-3107 delivers lenacapavir orally 1000 without a change in half-
Slide 33: INSTI Prodrug Bioavailability Enables Monthly Dosing
Leading HIV Innovation Setting a New HIV Treatment Standard Transforming HIV PrEP INSTI Prodrug Bioavailability Enables Monthly Dosing Once-Monthly Oral INSTI #1 Tablet Dog PK INSTI #2 Tablet Dog PK 1000000 1000000 INSTI #1 INSTI #2 GS-3242 Plasma Conc. (nM) GS-1219 Plasma Conc. (nM) 100000 100000 (
Slide 34: Comprehensive Treatment Pipeline
Leading HIV Innovation Setting a New HIV Treatment Standard Transforming HIV PrEP Comprehensive Treatment Pipeline Evaluating Profile for Combination Selecting Ideal Partner Advancing Forward Daily Oral Bictegravir + Lenacapavir Lenacapavir + Islatravir (NRTTI) Weekly Oral GS-4182 (LEN prodrug) + GS
Slide 35: LEN + GS-1614: Advancing Quarterly Regimen
Leading HIV Innovation Setting a New HIV Treatment Standard Transforming HIV PrEP LEN + GS-1614: Advancing Quarterly Regimen Quarterly Injectable Single SC Injection of GS-1614 in Non-Human Primates • GS-1614 as a prodrug delivers ISL to the plasma 10000 with half-life of >28 days in NHP, supporting
Slide 36: Comprehensive Treatment Pipeline
Leading HIV Innovation Setting a New HIV Treatment Standard Transforming HIV PrEP Comprehensive Treatment Pipeline Evaluating Profile for Combination Selecting Ideal Partner Advancing Forward Daily Oral Bictegravir + Lenacapavir Lenacapavir + Islatravir (NRTTI) Weekly Oral GS-4182 (LEN prodrug) + GS
Slide 37: LEN + bNAbs: First-in-Class Twice-Yearly Regimen
Leading HIV Innovation Setting a New HIV Treatment Standard Transforming HIV PrEP LEN + bNAbs: First-in-Class Twice-Yearly Regimen Twice-Yearly Injectable Virologic Outcomes at Week 26 94% • Proof-of-concept achieved in Phase 1b trial 79% • All participants who received LEN, TAB, and high-dose ZAB m
Slide 38: PK Support Twice-Yearly Dosing of High Potency INSTIs
Leading HIV Innovation Setting a New HIV Treatment Standard Transforming HIV PrEP PK Support Twice-Yearly Dosing of High Potency INSTIs Twice-Yearly Injectable Single SC injection in Non-Human Primates 400 mg fixed Cyno LAI SC PK • GS-1219 and GS-3242 selected for development 100000 • More potent an
Slide 39: Comprehensive Treatment Pipeline
Leading HIV Innovation Setting a New HIV Treatment Standard Transforming HIV PrEP Comprehensive Treatment Pipeline Evaluating Profile for Combination Selecting Ideal Partner Advancing Forward Daily Oral Bictegravir + Lenacapavir Lenacapavir + Islatravir (NRTTI) Weekly Oral GS-4182 (LEN prodrug) + GS
Slide 40: Bringing Up to 7 New Options for PWH by End of 2033
Leading HIV Innovation Setting a New HIV Treatment Standard Transforming HIV PrEP Bringing Up to 7 New Options for PWH by End of 2033 GS-3107 + QM INSTI Monthly Oral Bictegravir + Lenacapavir Lenacapavir + GS-1614 Daily Oral Quarterly Injectable Lenacapavir + Lenacapavir Lenacapavir + GS-4182 TAB +
Slide 41: Gilead Will Continue to be the Global Leader in HIV Innovation
Leading HIV Innovation Setting a New HIV Treatment Standard Transforming HIV PrEP Gilead Will Continue to be the Global Leader in HIV Innovation • Gilead has been a leader in HIV with its portfolio of market- Innovation leading products 1 Leader • Continuously delivering transformative treatment & p
Slide 42: Q&A
Johanna Mercier Tomas Cihlar, PhD Chief Commercial Officer SVP Research, Q&A Virology Discovery Jared Baeten, MD, PhD Tanya Monga SVP Virology SVP Global Commercial Therapeutic Area Head Strategy & Operations
Slide 43: Campus Lab Tour
Campus Lab Tour Joydeep Ganguly SVP Corporate Operations
Slide 44: Gilead Foster City Introduction
Gilead Foster City Introduction Foster City Map Master Plan Principles 4 Campus structured in 2 halves: South Campus dedicated to 1 R&D/Technical Ops, while North campus focused on G&A 1 South Campus consists of 10 new modern labs/pilot plants 2 aimed at frictionless technology transfer through co-l
Slide 45: Foster City South Campus Vision: 2027
South Campus: 2027 Vision Foster City South Campus Vision: 2027 ANALYTICAL FUTURE PROCESS BIOLOGICS CHEMISTRY DEVELOPMENT BIOLOGICS FORMULATION RESEARCH 355 357 RESEARCH HUB 333 NRC-331 368 New-335 353 324 362 VIROLOGY RESEARCH 342 346 PRE-CLINICAL CELL THERAPY RESEARCH RESEARCH 344
Slide 46: Sustainability @ Gilead
Sustainability @ Gilead On Track Progress Green Buildings in Network Strong Progress 100% 100% Anticipated Additions Green Certifications against 2030 pledges 11 Energy Savings Research Infrastructure Net Zero Buildings Target Achieved designed to be Green certified On track to achieve carbon pledge
Slide 47: Research Building – B324
Research Building – B324 Dedicated Research Building in Foster City Largest Research Building on Site At the Center of HQ’s South Campus 372k Sq Ft – Largest 2021 Facility of Year Award Over 20+ Digital use cases – dedicated Research site Winner Pharma 4.0 facility in CA (Only Research Lab to win aw
Slide 48: HIV Research Tour
HIV Research Tour Key Information Tour Details Name badge has your group assignment Staggered tour times, running every few minutes Meet at the event registration desk Please Remember No photography No food or drink Please keep your broader questions for the Q&A panel at the end 48
Slide 49: Agenda
Agenda Morning Session Afternoon Session 10:30am – 12:00pm 1:30pm – 3:00pm Leading HIV Innovation: Our Legacy & Our Future Transformational HIV PrEP Program & Strategy Welcome and Introduction Global Strategy for PrEP Daniel O’Day・ Chairman & CEO Tanya Monga・ SVP Global Commercial Strategy & Operati
Slide 50: Global Strategies for PrEP
Global Strategies for PrEP Ta n y a M o n g a SVP Global Commercial Strategy & Operations
Slide 51: Agenda
Agenda Morning Session Afternoon Session 10:30am – 12:00pm 1:30pm – 3:00pm Leading HIV Innovation: Our Legacy & Our Future Transformational HIV PrEP Program & Strategy Welcome and Introduction Global Strategy for PrEP Daniel O’Day・ Chairman & CEO Tanya Monga・ SVP Global Commercial Strategy & Operati
Slide 52: Under-Utilization of PrEP is a Global Issue
Leading HIV Innovation Setting a New HIV Treatment Standard Transforming HIV PrEP Under-Utilization of PrEP is a Global Issue Europe 2-15% United States ~33%, or 400K 1-20% 5-7% New HIV Infections: 39% Black → 14% PrEP utilization 7-28% 10-16% 31% Latine → 18% PrEP utilization 19% Women → 8% PrEP ut
Slide 53: Lenacapavir Sets a New Standard for HIV Prevention
Leading HIV Innovation Setting a New HIV Treatment Standard Transforming HIV PrEP Lenacapavir Sets a New Standard for HIV Prevention Cisgender Women Cisgender Men & Gender Diverse People 100% 99.9% of lenacapavir of lenacapavir participants did not participants did not acquire HIV acquire HIV Unmatc
Slide 54: Global Approach Maximizes Potential of LEN for PrEP
Leading HIV Innovation Setting a New HIV Treatment Standard Transforming HIV PrEP Global Approach Maximizes Potential of LEN for PrEPTM Global Launch Priorities Customized geographic strategy to maximize reach of twice-yearly lenacapavir for PrEP Key International Low- & Lower-Middle- U.S. PrEP Mark
Slide 55: Executing a Transformational PrEP Program
Executing a Transformational PrEP Program Moupali Das, MD, MPH Vi c e Pr es i d ent , C l i ni c a l D evel op m ent H I V Pr event i on & Ped i a t r i c s
Slide 56: Unprecedented Efficacy Across Phase 3 Trials
Leading HIV Innovation Setting a New HIV Treatment Standard Transforming HIV PrEP Unprecedented Efficacy Across Phase 3 Trials Cisgender Women Cisgender Men & 2.41 Gender Diverse People 2.37 Incidence of HIV Infection Incidence of HIV Infection 2.02 per 100 Person-Yr per 100 Person-Yr 1.69 0.93 0.00
Slide 57: Most Comprehensive HIV Prevention Program
Leading HIV Innovation Setting a New HIV Treatment Standard Transforming HIV PrEP Most Comprehensive HIV Prevention Program PURPOSE Driven Clinical Program Across >9,000 participants in 5 continents Cisgender women in South Cisgender men and gender diverse people in Argentina, Cisgender women in U.S
Slide 58: Injection Site Reactions are Low-Grade & Manageable
Leading HIV Innovation Setting a New HIV Treatment Standard Transforming HIV PrEP Injection Site Reactions are Low-Grade & Manageable Pain Swelling Erythema PURPOSE 1 PURPOSE 2 PURPOSE 1 PURPOSE 2 LEN PBO LEN PBO LEN PBO LEN PBO 100 80 60 40 20 0 BL W26 W52 BL W26 W52 BL W26 W52 BL W26 W52 BL W26 W5
Slide 59: Lenacapavir Administration Results in a Drug Depot
Leading HIV Innovation Setting a New HIV Treatment Standard Transforming HIV PrEP Lenacapavir Administration Results in a Drug Depot Lenacapavir is administered as two 1.5mL SC injections that create a drug depot Nodules are generally low- grade, palpable, not visible & lessen over time ~95% continu
Slide 60: Extending the Potential of PrEP Towards Once-Yearly
Leading HIV Innovation Setting a New HIV Treatment Standard Transforming HIV PrEP Extending the Potential of PrEP Towards Once-Yearly 2012 & 2019 2025 2028+ Daily Oral Twice-Yearly Injectable Long-Acting Oral Truvada & Descovy Lenacapavir e.g., GS-3107 for potential • Truvada launched as the first •
Slide 61: Redefining HIV Prevention
Redefining HIV Prevention Johanna Mercier Chief Commercial Officer
Slide 62: Lenacapavir Will Revolutionize HIV Prevention
Leading HIV Innovation Setting a New HIV Treatment Standard Transforming HIV PrEP Lenacapavir Will Revolutionize HIV Prevention “Revolutionary. A game changer. Spine chilling.” “This is so far superior to any other prevention method we have, that it’s unprecedented” -Winnie Byanyima, Executive Direc
Slide 63: Gilead is a Leader in HIV Prevention
Leading HIV Innovation Setting a New HIV Treatment Standard Transforming HIV PrEP Gilead is a Leader in HIV Prevention Descovy for PrEP Consumers YoY Market Growth Adherence Market Share >400K +10-15% 40-45% 50-55% ….Despite Progress, Substantial Unmet Need Remains as 80% of PrEP Consumers Want a Lo
Slide 64: Lessons Learned from Current Injectable HIV Regimens
Leading HIV Innovation Setting a New HIV Treatment Standard Transforming HIV PrEP Lessons Learned from Current Injectable HIV Regimens Required Major Office Education on Injection Adherence Burden on Asynchronous with Protocol and Systems Technique HCP and Office Regular STI/HIV Testing Change Under
Slide 65: Three Strategic Imperatives For Success
Leading HIV Innovation Setting a New HIV Treatment Standard Transforming HIV PrEP Three Strategic Imperatives For Success Establish Expand the PrEP Deliver smooth, lenacapavir for market consistent, positive PrEP as new by educating new and existing customer-centric standard of care providers as wel
Slide 66: Lenacapavir: A Class of its Own in HIV Prevention
Leading HIV Innovation Setting a New HIV Treatment Standard Transforming HIV PrEP Establish Lenacapavir: A Class of its Own in HIV Prevention Novel Dosing Schedule Subcutaneous 2 Visits Yearly1 and Delivery, and Opportunity to administer in a Reduced customer and office burden variety of office sett
Slide 67: Positive Momentum for PrEP Access
Leading HIV Innovation Setting a New HIV Treatment Standard Transforming HIV PrEP Establish Positive Momentum for PrEP Access • Growing support for PrEP coverage with limited restrictions and $0 cost-sharing >90% Total Coverage • U.S. Preventative Services Task Force (USPSTF) Guidance: October 2024
Slide 68: Lenacapavir Expected to have ~90% Coverage by Year 1
Leading HIV Innovation Setting a New HIV Treatment Standard Transforming HIV PrEP Expand Lenacapavir Expected to have ~90% Coverage by Year 1 ~90% 55% 20% ~75% Medical & Medical Pharmacy Benefit Benefit Only 15% 10% Pharmacy Not Covered Benefit Only 6 Months ~12 Months 68 New Disclosure
Slide 69: Favorable Channel Mix for Lenacapavir for PrEP
Leading HIV Innovation Setting a New HIV Treatment Standard Transforming HIV PrEP Expand Favorable Channel Mix for Lenacapavir for PrEP PrEP Payer Mix PrEP Channel Mix Daily Long Acting Acquisition Oral Injectable ~25 to 30% Pathways ~20 to 30% ~50 to 60% 340B 340B ~15 to 20% Acquisition pathway wil
Slide 70: Well-Positioned to Significantly Expand U.S. Market
Leading HIV Innovation Setting a New HIV Treatment Standard Transforming HIV PrEP Expand Well-Positioned to Significantly Expand U.S. Market 1M+ High Untapped Potential 400K+ 300K+ (for PrEP) (for PrEP) 2012 2019 2022 2024 mid-2030s 70
Slide 71: Starting w/Future in Mind to Enable Launch Success
Leading HIV Innovation Setting a New HIV Treatment Standard Transforming HIV PrEP Expand Starting w/Future in Mind to Enable Launch Success Consumers HCPs Individuals with a New Specialties (e.g., Normalizing Bacterial STI Primary Care, OBGYN) People Who Inject New Settings (e.g., Drugs College Heal
Slide 72: Track Record of Insights-Driven Consumer Engagement
Leading HIV Innovation Setting a New HIV Treatment Standard Transforming HIV PrEP Customer Track Record of Insights-Driven Consumer Engagement +1,000 feet of 21 hours per Week >2 Hours on TikTok Content Scrolled on Consumer Spent Gaming Per Day Instagram a Day Facts: First in HIV Pharma Mobile Game
Slide 73: Deliver Smooth & Consistent Provider Experience
Leading HIV Innovation Setting a New HIV Treatment Standard Transforming HIV PrEP Customer Deliver Smooth & Consistent Provider Experience Reimbursement & Logistics and For Office Administration Product Acquisition Adherence providers Field Reimbursement Team Partner with specialty Injection d
Slide 74: Deliver Smooth & Consistent Consumer Experience
Leading HIV Innovation Setting a New HIV Treatment Standard Transforming HIV PrEP Customer Deliver Smooth & Consistent Consumer Experience Reimbursement & Logistics and Office Administration Product Acquisition Adherence Consumers Instructions for coverage, testing Clear messaging and after-care
Slide 75: Igniting a PrEP Revolution…Beginning with the U.S.
Leading HIV Innovation Setting a New HIV Treatment Standard Transforming HIV PrEP Igniting a PrEP Revolution…Beginning with the U.S. Comprehensive Customized Market Roles to Enable Expansion Smooth Access Strategy & Acquisition Experts in Gilead – Leaders Insights-Driven Early and Broad Consumer in
Slide 76: Targeted Approach Required to Unlock LEN Potential ex-U.S.
Leading HIV Innovation Setting a New HIV Treatment Standard Transforming HIV PrEP Targeted Approach Required to Unlock LEN Potential ex-U.S. • HIV diagnoses up 50% (2022>2023), particularly Incidence (annual) 6,000 heterosexual Current PrEP use 20% • <5% PrEP users Black African, but group represent
Slide 77: Rapid & Sustainable Access Will Drive LLMIC Adoption
Leading HIV Innovation Setting a New HIV Treatment Standard Transforming HIV PrEP Rapid & Sustainable Access Will Drive LLMIC Adoption Goal Achieve broad, sustainable access that optimizes availability, uptake, and outcomes with lenacapavir for PrEP LLMIC Aligned access plan focused on: Speed Volume
Slide 78: Lenacapavir Will Catalyze the HIV PrEP Market Globally
Leading HIV Innovation Setting a New HIV Treatment Standard Transforming HIV PrEP Lenacapavir Will Catalyze the HIV PrEP Market Globally 2024 Mid-2030s Global PrEP Market >40% >60% U.S. Gilead Share Descovy Only Descovy & Lenacapavir LA Injectable Long-Acting MSM (White, Black, Latine), PrEP PrEP Co
Slide 79: Lenacapavir Enables Innovative Approach to PrEP
Lenacapavir Enables Innovative Approach to PrEP Unprecedented • 100% in PURPOSE 1 & 99.9% in PURPOSE 2 did not acquire HIV infection 1 Efficacy & • Manageable and self-resolving injection-site reactions Demonstrated Safety • Diverse program enrolling >9,000 participants across 5 continents Transform
Slide 80: Q&A
Johanna Mercier Jared Baeten, MD, PhD Chief Commercial Officer SVP Virology Q&A Therapeutic Area Head Tanya Monga SVP Global Commercial Strategy & Operations
Slide 81: Extending Our HIV Leadership Into Late 2030s & Beyond
Extending Our HIV Leadership Into Late 2030s & Beyond SETTING A NEW STANDARD IN HIV TREATMENT TRANSFORMATIONAL HIV PREVENTION Next Wave of Gilead HIV Innovation Unparalleled PrEP Program Meaningfully Extends Our Leadership Offers New Possibilities • Annual ~2-3% treatment market growth • Lenacapavir
Slide 82: HIV Analyst & Investor Event
HIV Analyst & Investor Event 10 December 2024 10 December 2024 FOR INVESTOR USE ONLY, NOT FOR PROMOTIONAL USE.